What is more, we performed subclass mapping to compare the expression profile of the high/low subgroups and another published dataset containing 47 patients with melanoma that responded to immune checkpoint inhibitors (CTLA-4 and PD-1) (Roh et al., 2017). This evidence concerns the gene CTLA4 and melanoma.